Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Video Interview: C4 Therapeutics Targets Protein Degradation

This article was originally published in Scrip

Executive Summary

Finding a way to trick the ubiquitin proteasome system, C4 Therapeutics, a spin-out from Harvard's Dana-Farber Cancer Institute, has developed a method to target any disease-causing protein for degradation. Fresh from announcing the creation of the company, a $73m series A financing, and a deal with Roche which has a potential biodollar value north of $750m, C4 Therapeutics co-founder and executive chair Marc Cohen explains to Informa Pharma Insights global director of content Mike Ward how the approach works.


Related Content

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts